Abbott says its HeartMate 3 LVAD is clinically proven to extend life by five years or more — but thousands of people in the U.S. still die of heart failure within a year. Kyree Miller, a 30-year-old college student, navigated seven long years of heart failure with the assistance of an Abbott HeartMate left ventricular […]
Structural Heart
FDA clears Teleflex’s Wattson temporary pacing guidewire
Teleflex (NYSE:TFX) announced today that it received FDA clearance for its Wattson temporary pacing guidewire for use in heart procedures. Wayne, Pennsylvania-based Teleflex says it’s the first commercially available bipolar temporary pacing guidewire designed specifically for use during TAVR and BAV. The company plans to feature Wattson at TVT: The Structural Heart Summit, June 7-10 […]
Inari Medical launches RevCore, Triever16 Curve catheters
Inari Medical today announced it launched two new catheters for venous stent thrombosis and venous thromboembolism. The Irvine, California-based company launched its RevCore thrombectomy catheter and the Triever16 Curve catheter. RevCore is a mechanical thrombectomy device for venous in-stent thrombosis, and Triever16 Curve is for pulmonary embolism and peripheral thrombectomy. “We are thrilled to announce […]
Conformal Medical raises $35M in oversubscribed Series D
Conformal Medical today announced the successful completion of its Series D funding round, where it raised a total of $35 million. The oversubscribed Series D was led by Sprig Equity, with participation from all major Series C investors. “Sprig Equity is focused on enabling transformative medical technology companies to achieve meaningful milestones and, more importantly, […]
Abiomed recalls some Impella 5.5 with SmartAssist devices
The FDA today issued a field safety notice deeming a recall of Abiomed Impella 5.5 heart pumps as Class I, the most serious kind. Abiomed — bought by Johnson & Johnson for $16.6 billion last year — recalled 466 affected devices. It distributed these Impella 5.5 with SmartAssist devices between Sept. 28, 2021, and March […]
The top cardiac care innovation news at Heart Rhythm 2023
The future of cardiac care was on display at the Heart Rhythm Society’s 2023 annual meeting. Medical device companies showcased groundbreaking technologies at Heart Rhythm 2023, May 19-21 in New Orleans. The innovations presented during the event offer new avenues for diagnosis, treatment, and monitoring of cardiovascular conditions, providing hope for patients worldwide. Boston Scientific, […]
Boston Scientific won’t buy majority stake in M.I. Tech
Boston Scientific (NYSE:BSX) will no longer be acquiring a majority stake in Korea-based medical device manufacturer M.I. Tech. The Marlborough, Massachusetts-based company announced plans to acquire a 64% stake in M.I. Tech in June 2022. It valued the deal at approximately $230 million. At the time, the company expected to close the transaction by the end […]
Medtronic reports positive Harmony transcatheter pulmonary valve data
Medtronic (NYSE:MDT) announced positive two-year results for a study of its Harmony transcatheter pulmonary valve (TPV) system. Harmony treats severe pulmonary regurgitation (PR) in the native or surgically repaired right ventricular outflow tract (RVOT). The Medtronic analysis demonstrates strong clinical and hemodynamic outcomes for patients with a congenital heart defect of the RVOT. The current […]
Boston Scientific reports positive Farapulse, Watchman FLX data
Boston Scientific (NYSE:BSX) announced data supporting its pulsed-field ablation (PFA) and left atrial appendage closure (LAAC) systems. Studies backed the company’s key electrophysiology and cardiac rhythm management therapies, plus the Watchman FLX device. In addition to the LAAC device, the Marlborough, Massachusetts-based company shared data on its Farapulse PFA system, POLARx cryoablation system and the […]
Study supports extravascular ICD from Medtronic
Medtronic (NYSE:MDT) announced positive long-term follow-up results for its investigational implantable cardioverter defibrillator (ICD). The medtech giant designed its extravascular (EV) ICD system to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. Medtronic’s EV ICD pivotal study followed patients through an average of 17.1 months. The company presented data as late-breaking […]
Data backs Abbott Aveir dual-chamber leadless pacemaker
Abbott (NYSE:ABT) today announced late-breaking results from a study of its Aveir dual-chamber (DR) i2i leadless pacemaker. The data came from the company’s large-scale FDA investigational device exemption (IDE) study. It assesses Aveir DR, the world’s first dual-chamber leadless pacemaker for safety and performance. Abbott said the data suggests that Aveir DR could offer new […]
